ArticleCancers2024
A Hybrid Deep Learning and Machine Learning Approach with Mobile-EfficientNet and Grey Wolf Optimizer for Lung and Colon Cancer Histopathology Classification.
Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Hybrid Decision-Level Fusion of CNN-Based Deep and Handcrafted Features for Colon Cancer Classification.Journal of imaging · 2026Article
- A Hybrid Lung and Colon Histopathological Image Classification Framework Using MobileNetV3-Small Deep Features and Differential Evolution Optimization.Diagnostics (Basel, Switzerland) · 2026Article
- Artificial intelligence in immunotherapy: revolutionizing diagnostic and therapeutic applications in cancer and autoimmune diseases.Clinical and experimental medicine · 2026Review
- Compact deep learning models for colon histopathology focusing performance and generalization challenges.Scientific reports · 2026Article
- Grad-CAM based deep learning analytics for image-level colon disease classification based on graph neural networks and vision transformers.Frontiers in physiology · 2026Article
- Development and validation of an interpretable machine learning model for predicting chemotherapy-induced neutropenia in small cell lung cancer: a web-based clinical decision support tool.Frontiers in oncology · 2026Article
- A Lightweight Cross-Gated Dual-Branch Attention Network for Colon and Lung Cancer Diagnosis from Histopathological Images.Medical sciences (Basel, Switzerland) · 2025Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundLung and colon cancers are among the most prevalent and lethal malignancies worldwide, underscoring the urgent need for advanced diagnostic methodologies. This study aims to develop a hybrid deep learning and machine learning framework for the classification of Colon Adenocarcinoma, Colon Benign Tissue, Lung Adenocarcinoma, Lung Benign Tissue, and Lung Squamous Cell Carcinoma from histopathological images.
methodsCurrent approaches primarily rely on the LC25000 dataset, which, due to image augmentation, lacks the generalizability required for real-time clinical applications. To address this, Contrast Limited Adaptive Histogram Equalization (CLAHE) was applied to enhance image quality, and 1000 new images from the National Cancer Institute GDC Data Portal were introduced into the Colon Adenocarcinoma, Lung Adenocarcinoma, and Lung Squamous Cell Carcinoma classes, replacing augmented images to increase dataset diversity. A hybrid feature extraction model combining MobileNetV2 and EfficientNetB3 was optimized using the Grey Wolf Optimizer (GWO), resulting in the Lung and Colon histopathological classification technique (MEGWO-LCCHC). Cross-validation and hyperparameter tuning with Optuna were performed on various machine learning models, including XGBoost, LightGBM, and CatBoost.
resultsThe MEGWO-LCCHC technique achieved high classification accuracy, with the lightweight DNN model reaching 94.8%, LightGBM at 93.9%, XGBoost at 93.5%, and CatBoost at 93.3% on the test set.
conclusionsThe findings suggest that our approach enhances classification performance and offers improved generalizability for real-world clinical applications. The proposed MEGWO-LCCHC framework shows promise as a robust tool in cancer diagnostics, advancing the application of AI in oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.